Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00185523 · ClinicalTrials.gov registry record
Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 88
- Enrollment target
NCT00185523: Clinical Trial study, sponsored by Stanford University.
NCT00185523 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 88 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00185523 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 88 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the overall and disease free survival of recipients who have received G-CSF mobilized stem cells from HLA matched sibling donors.
Interventions
- PROCEDURE Allogeneic hematopoietic cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2002-05 |
| Est. Completion | 2009-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00185523
The ClinicalTrials.gov registry entry for NCT00185523 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allogeneic hematopoietic cell transplantation is the first listed.
NCT00185523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00185523 about?
NCT00185523 is a clinical study titled "Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)". The purpose of the study is to evaluate the overall and disease free survival of recipients who have received G-CSF mobilized stem cells from HLA matched sibling donors.
What is the current status of trial NCT00185523?
This trial is currently terminated. The enrollment target is 88 participants. The study started on 2002-05. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00185523?
The interventions under investigation include: Allogeneic hematopoietic cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00185523?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.